Theralase Technologies Inc. V.TLT

All things considered.

[jmm1228]

Theralase is likely on the threshold of a major triumph in the treatment of cancer and some other diseases.

It has none of the characteristics inherent of the major successful pharmas. Less than 20 employees whosse main responsibility is overseeing trial patients and preparing reports.

With expected FDA approvals in the near term what is in place to serve the expected demand and associated service issues? Nothing.

Most seasoned executives, IMO, assessing the situation, would conclude that the way forward calls for a transfer of the TLT assets to an entity with all the management structure in  place necessary to secure the potential opportunities expeditiously.

RDW is too smart not to know this.

[gebremeskel]

Theralase just needs a distribution partner.

[BlueFranky]

One of the more insightful pieces of logic I've yet read on this board.. like a mirror staring Mr White in the face. A sober reminder of what absolutely must be going on in the background and perhaps for quite some time! 

[O12009]

I would imagine this is some of the talks that was mentioned in the update. A joint venture partnership to move the bladder cancer treatment to commercialization. If this happens in January we might not see a PP until February. Of course other talks would be ongoing for vaccines partners and maybe we could see a big pharmaceutical who wants to try a combo trial with a cancer drug they have that

[Lesalpes29]

I agree a lot of possibilities in front of RDW and management. They only need to be open and not drop the ball. On the science side we are in good position to get something good in the near futur. Last message from MP was positive as usual and to see the name Dr Lbiati in it was positive too. A sign that we are close to some sort of a deal...maybe? GL

[DeathXray33]

"About CREST The CREST trial is a Phase 3, multinational, randomized, open-label, three parallel-arm study of sasanlimab, an anti-PD-1 mAb, in combination with BCG (BCG induction with or without BCG maintenance) versus BCG (induction and maintenance) in participants with BCG-nave, high-risk NMIBC. Patients were randomized to receive sasanlimab 300 mg by subcutaneous (SC) injection EVERY FOUR